- Home
- DYAI vs PLUR Comparison
DYAI vs PLUR Comparison
Compare DYAI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | PLUR |
|---|---|---|
| Founded | 1979 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 31.5M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | DYAI | PLUR |
|---|---|---|
| Price | $0.96 | $3.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 496.0K | 50.9K |
| Earning Date | 11-12-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,342,195.00 | $1,326,000.00 |
| Revenue This Year | $12.52 | $97.38 |
| Revenue Next Year | $92.04 | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 121.74 |
| 52 Week Low | $0.71 | $2.82 |
| 52 Week High | $2.14 | $7.13 |
Technical Indicators
Market Signals| Indicator | DYAI | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 42.67 |
| Support Level | $0.80 | $3.20 |
| Resistance Level | $1.04 | $3.72 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 63.14 | 28.18 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.